CONPHARM AB

CONPHARM AB

Previous company name

Name change date

Company Overview
Conpharm AB is an independent Swedish pharmaceutical company, primarily engaged in the development and distribution through licensees, pharmaceutical products which are based on substances extracted from the podophyllum plant. Podophyllum, is an Indian plant in which natives of Himalayan region knew that an aqueous extract of the dried roots could be used as a purgative. Extract of the herb was used in China as an anti-tumor drug for more than 2000 years ago, and a crude extract was also used in the treatment of snake bites, peridontitis, skin disorders, coughs and against various intestinal worm diseases.
In 1998, Conpharm has applied to the Swedish Medical Products Agency for registration of its anti-arthritic drug Reumacon. Reumacon has been shown to possess good anti-rheumatic efficacy, significantly superior to placebo and comparable to methotrexate and other DMARD’s. Reumacon suppresses the activity of rheumatoid arthritis, including number of swollen joints and pain.
Conpharm, headquartered in Uppsala, Sweden, has partnership with Switzerland’s Analytecon S.A, to develop manufactures and supplies the active ingredients in which Conpharm bases its products.
Business Summary
Conpharm AB operates as a pharmaceutical company. It markets, through licenses, pharmaceutical products based on substances extracted from the Podophyllum plant. The company’s products primarily include WARTEC, which is used for treating genital warts; and REUMACON, a drug for treating patients with rheumatoid arthritis, which is in clinical programs.
Description and history
Conpharm is a pharmaceutical company headquartered in Uppsala, Sweden.

The company markets, through licenses, pharmaceutical products based on substances extracted from the Podophyllum plant. These substances affect the immunological system and influence viral development.

The technical know-how required to obtain the substances in pharmaceutical grade from the Podophyllum plant is available in terms of an agreement with a partner specialized in this field – Analytecon S.A., Couvet, Switzerland. Analytecon develops, manufactures and supplies the active ingredients on which Conpharm bases its products.

Business Line
Engaged in the development and distribution through licensees, pharmaceutical products which are based on substances extracted from the podophyllum plant
Subsidiary

Advisor
ERNST & YOUNG AB
IPO date

US SIC Code
2834
Company Address
UPPSALA SCIENCE PARK

City province or state postal code
751 83, UPPSALA
Phone: +46 18 19 49 50
Fax: +46 18 55 80 86
Country address: SWEDEN
Website url: www.conpharm.se